Results 101 to 110 of about 168,234 (309)
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
MedicinaObjective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders.
Keming Gao +2 more
doaj +1 more source
Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
PLoS ONE, 2014 ObjectivesInflammation is involved in the pathogenesis of depression. A few cross-sectional population-based studies have found that depression is associated with increased levels of inflammatory markers. Soluble urokinase plasminogen activation receptor
Eva Haastrup +5 more
doaj +1 more source
Archives of Pharmacy Practice, 2013 While major depression is considered a frequent mental illness there are ongoing reports of high non-adherence to antidepressant medications which places suffers at high risk for relapse, recurrence, or greater impairment,. The World Health Organization (
Abimbola Farinde
doaj +1 more source
A retrospective case-control study on the prescribing practices of antidepressants administered to cancer patients and non-cancer patients in Australia [PDF]
, 2016 Comorbidity of depression risks is common among cancer patients. The pharmacological treatment of depression is antidepressants. However, antidepressants may interact with anticancer drugs or cause adverse reactions.
Sanjida, Saira
core
Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study [PDF]
OBJECTIVE: To estimate risks of major congenital anomaly (MCA) among children of mothers prescribed antidepressants during early pregnancy or diagnosed with depression but without antidepressant prescriptions.
Fiaschi, Linda +8 more
core +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Antidepressants- Stratified Subgroup Meta-Analyses.
, 2017 Forest plots showing the summary effect sizes for levels of BDNF pre- and post- different kind of antidepressant drugs treatment (less than 12 week). (A) using SSRIs;(B) using SNRIs.
Bin Zou (539731) +10 more
core +1 more source
Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology, EarlyView.Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
European PsychiatryBackground Despite uncertain benefits, antidepressants are used in the management of personality disorders (PDs). We investigated the association between antidepressants and two adverse outcomes - suicidal behaviour and violent crimes - in individuals ...
Kimmo Herttua +3 more
doaj +1 more source